We explored the mechanisms of cisplatin resistance in a series of bladder transitional carcinoma cells that are either sensitive or progressively resistant to cisplatin. Resistant lines were raised by chronic exposure of the parental cells to progressively increased concentrations of cisplatin. The cisplatin IC50s of the sensitive and the three resistant cells were 4.3, 25.0, 40.4, and 52.2 microM, respectively. The expressions of glutathione S-transferase pi (GST-pi) and multidrug resistance-associated protein (MRP) were enhanced in a dose-response manner as cells acquired progressive cisplatin resistance. Expression of mdr-1 transcript was detected in the three resistant lines but not in the sensitive line. Glutathione contents were increased in resistant cells, yet the trend of increase did not reach statistical significance (p = 0.061). In conclusion, transitional carcinoma cells may gain cisplatin resistance through multiple pathways including up-regulation of GST-pi, MRP and possibly mdr-1. Glutathione contents may play a less significant role in cisplatin chemoresistance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Outcomes of total cystectomy with medical treatment in canine urothelial carcinoma of the bladder trigone.
Can Vet J
March 2025
Veterinary Medical Center (Takahashi, Motegi, Fujita, Hashimoto) and Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences (Kato, Nakagawa, Nishimura) and Laboratory of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences (Maeda), The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Objective: This study aimed to evaluate outcomes and complications in dogs with urothelial carcinoma (UC) of the bladder trigone treated with total cystectomy using uretero-prepuce/vagina/cutaneous anastomosis combined with medical treatment.
Animals: Twenty-one dogs.
Procedure: Total cystectomy was completed as follows: The whole bladder and urethra were removed, and the ureters were anastomosed to the skin in 1 case and to the vagina in 9 cases in females.
Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Netw Open
March 2025
Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
Importance: Metastatic urothelial carcinoma (mUC) presents a therapeutic challenge with poor outcome. Enfortumab vedotin has emerged as a promising treatment, necessitating a comprehensive evaluation of its effectiveness and safety.
Objective: To synthesize the available evidence on enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, as an mUC treatment for the purpose of guiding clinical decision-making and future research.
A histopathological snapshot of bladder cancer: a Johannesburg experience of 1480 histopathology reports.
World J Urol
March 2025
Department of Anatomical Pathology, University of the Witwatersrand, /National Health Laboratory Services, Johannesburg, South Africa.
Purpose: To evaluate the histopathological characteristics of bladder cancer in patients presenting to Johannesburg hospitals over a 13-year period (2010-2023).
Methods: Following ethical clearance, a retrospective observational, descriptive review of histopathological reports over 13 years was conducted in Johannesburg. Inclusion criteria was bladder biopsies, TURBT specimens, and radical cystectomy (RC) specimens positive for bladder cancer.
Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
World J Urol
March 2025
Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Introduction: Disitamab Vedotin (DV, RC48, or RC48-ADC) is a novel humanized antibody-drug conjugate (ADC), which is based on human epidermal growth factor receptor 2 antibody (anti-HER2, or hertuzumab) coupled with monomethyl auristatin E (MMAE). This study aims to evaluate the efficacy and safety of RC48-ADC in combination with programmed cell death protein 1 (PD-1) inhibitors for treatment of locally advanced or metastatic urothelial carcinoma (la/mUC) patients.
Patients And Methods: This is a retrospective and real-world investigation originated from an enrollment of locally advanced or mUC patients underwent treatments with RC48-ADC in combination with PD-1 inhibitors in two hospitals, between August 2022 and July 2024.
Competing Risk Analysis for Diabetes Mellitus Mortality in Bladder Cancer Patients: A Population-based Study.
Curr Cancer Drug Targets
March 2025
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Background: Historically, there has been a lack of focus on the mortality rates of individuals with both diabetes and Bladder Bancer (BC). Our study aimed to identify the risk factors associated with death from Diabetes Mellitus (DM) in BC patients.
Methods: Data was gathered from the SEER database on individuals who were diagnosed with BC between the years 2000 and 2017.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!